Skip to main content
Clinical Trials/CTRI/2025/06/088927
CTRI/2025/06/088927
Completed
Phase 2/3

A Prospective Randomized Study to Compare the Post operative side effects of sugammadex vs neostigmine for reversal of vecuronium-induced neuromuscular blockade in patients undergoing CORONARY ARTERY BYPASS GRAFTING off pump

Kiranmuthrajah1 site in 1 country112 target enrollmentStarted: June 28, 2025Last updated:

Overview

Phase
Phase 2/3
Status
Completed
Sponsor
Kiranmuthrajah
Enrollment
112
Locations
1
Primary Endpoint
Time from reversal administration at least 3 TOFR equal to or more than 0.9

Overview

Brief Summary

This prospective, randomized clinical study was designed to compare the postoperative side effects of sugammadex versus neostigmine in reversing vecuronium - induced neuromuscular blockade in patients undergoing off-pump coronary artery bypass grafting (CABG). Eligible patients were randomly allocated to receive either sugammadex or neostigmine at the end of surgery. The objectives of the study was time to onset of train of four from time of administration of reversal agents and evaluations of postoperative complications such as bradycardia, hypotension, nausea, vomiting, residual neuromuscular blockade, need for NIV support, need for reintubation ,cardiac arrest. The aim of the study was to determine safer and more effective reversal agent in context of CABG-off pump surgeries, where rapid and smooth recovery from neuromuscular blockade is critical.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
Participant and Outcome Assessor Blinded

Eligibility Criteria

Ages
18.00 Year(s) to 90.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • 18 years of age or older
  • Scheduled for elective cardiac surgery with general anesthesia, invasive mechanical ventilation, complete median sternotomy.

Exclusion Criteria

  • Age less than 18 years
  • Patient scheduled for emergency or redo surgeries
  • Patients with history of COPD / Pulmonary hypertension / hepatic or renal dysfunction.

Outcomes

Primary Outcomes

Time from reversal administration at least 3 TOFR equal to or more than 0.9

Time Frame: 3 minutes / 5 minutes / 10 minutes / 20 minutes / 30 minutes / 1 hour / 2 hour

Secondary Outcomes

  • Time of extubation from discontinuation of inhaled anaesthetic,(Need for reintubation,)

Investigators

Sponsor
Kiranmuthrajah
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

Dr Kiran Muthu Rajah

Sri Ramachandra Institute of Higher Education and Research

Study Sites (1)

Loading locations...

Similar Trials